Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?

Antioxidants and Redox Signaling

Volumn 14, Issue 5, 2011, Pages 767-775

  Weinreb, Orly ^a   Bar Am, Orit ^a   Prosolovich, Ksenia ^a   Amit, Tamar ^a   Youdim, Moussa B H ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; HYDROGEN PEROXIDE; LACTACYSTIN; OXIDOPAMINE; RASAGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINE BRAIN LEVEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE DEHYDROGENATION; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRIATE CORTEX; STRIATONIGRAL DEGENERATION;

ACETYLCYSTEINE; ANIMALS; CATALASE; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; HYDROGEN PEROXIDE; INDANS; MALE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY;

PARKINSONIA; RATTUS;

EID: 79551673811     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3282     Document Type: Article

References (30)

1. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, and Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434: 109-116, 2002.
2. Bar-Am O, Weinreb O, Amit T, and Youdim MB. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-Parkinsonian drug rasagiline. J Neurochem 112: 1131-1137, 2010.
3. Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, and Mattevi A. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J Med Chem 48: 8148-8154, 2005.
4. Brotchie GM, Johnston TH, Visanji N, Pires P, Thiele S, Fitzer-Attas C, Montezinho LCP, Mrk A, and Thomsen C. 1-aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinsons disease Park Rel Dis Supp 2: S102, 2007.
5. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Capobianco L, de Blasi A, Battaglia G, Nicoletti F, Ruggieri S, and Paparelli A. Similarities between methamphetamine toxicity and proteasome inhibition. Ann N Y Acad Sci 1025: 162-170, 2004.
6. Gassen M, Lamensdorf I, Armony T, Finberg JP, and Youdim MB. Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. J Neural Transm 110: 171-182, 2003.
7. Lazzeri G, Lenzi P, Gesi M, Ferrucci M, Fulceri F, Ruggieri S, Bruno V, and Fornai F. In PC12 cells neurotoxicity induced by methamphetamine is related to proteasome inhibition. Ann N Y Acad Sci 1074: 174-177, 2006.
8. McNaught KS, Bjorklund LM, Belizaire R, Isacson O, Jenner P, and Olanow CW. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13: 1437-1441, 2002.
9. McNaught KS and Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinsons disease. Neurobiol Aging 27: 530-545, 2006.
10. Mehta A and Chesselet MF. Effect of GABA(A) receptor stimulation in the subthalamic nucleus on motor deficits induced by nigrostriatal lesions in the rat. Exp Neurol 193: 110-117, 2005.
11. Miller RL, James-Kracke M, Sun GY, and Sun AY. Oxidative and inflammatory pathways in Parkinsons disease. Neurochem Res 34: 55-65, 2009.
12. Murphy TH, Schnaar RL, and Coyle JT. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4: 1624-1633, 1990.
13. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, and Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinsons disease. N Engl J Med 361: 1268-1278, 2009.
14. Olsson M, Nikkhah G, Bentlage C, and Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15: 3863-3875, 1995.
15. Ou XM, Lu D, Johnson C, Chen K, Youdim MB, Rajkowska G, and Shih JC. Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res 16: 148-159, 2009.
16. Qiu JH, Asai A, Chi S, Saito N, Hamada H, and Kirino T. Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J Neurosci 20: 259-265, 2000.
17. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, and Stern GM. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542-544, 1978.
18. Rideout HJ and Stefanis L. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci 21: 223-238, 2002.
19. Shachar DB, Kahana N, Kampel V, Warshawsky A, and Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46: 254-263, 2004.
20. Smith MP and Cass WA. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinsons disease. Neuroscience 144: 1057-1066, 2007.
21. Speiser Z, Levy R, and Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Supplement 52: 287-300, 1998.
22. Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, and Finberg J. (R)()-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl 52: 301-305, 1998.
23. Tazik S, Johnson S, Lu D, Johnson C, Youdim MB, Stockmeier CA, and Ou XM. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasoneinduced brain cell apoptosis. Neurotox Res 15: 284-290, 2009.
24. Waldmeier PC. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J Neural Transm Suppl 23: 55-72, 1987.
25. Weinreb O, Amit T, Bar-Am O, and YoudimMB. Rasagiline; a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 92: 330-344, 2010.
26. Weinreb O, Bar-Am O, Amit T, and Youdim MB. The novel cholinesterase-The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact 175: 318-326, 2008.
27. Yoshida T, Yamada Y, Yamamoto T, and Kuroiwa Y. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 16: 129-136, 1986.
28. Youdim MBH and Tipton KF. Rat striatal monoamine oxidases inhibition by I-deprenyl and rasagiline: its relationship to 2-phenylethylaminenduced stereotypy and parkinsons disease. Parkinsonism Relat Disord 8: 247-253, 2002.
29. Zhang L, Yu H, Sun Y, Lin X, Chen B, Tan C, Cao G, and Wang Z. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol 564: 18-25, 2007.
30. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, and Le W. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystininduced nigrostriatal dopaminergic degeneration. J Neurochem 105: 1970-1978, 2008.